Evidence map›Paper›PMID 33133093›Full record

ArticleFrontiers in immunology2020

Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.

Darienne R Myers, Clare L Abram, David Wildes, Amira Belwafa, Alia M N Welsh, Christopher J Schulze, Tiffany J Choy, Tram Nguyen, Neil Omaque, Yongmei Hu and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. A druggable redox switch on SHP1 controls macrophage inflammation.bioRxiv : the preprint server for biology · 2026
    Article
  3. CAR-macrophages: a new chapter in cancer immunotherapy.Acta biochimica et biophysica Sinica · 2026
    Article
  4. Article
  5. Loss of SHP-1 in CD11cFrontiers in immunology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. CAR-armored-cell therapy in solid tumor treatment.Journal of translational medicine · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Darienne R MyersRevolution Medicines, Inc., Redwood City, CA, United States.
Clare L AbramDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States.
David WildesRevolution Medicines, Inc., Redwood City, CA, United States.
Amira BelwafaRevolution Medicines, Inc., Redwood City, CA, United States.
Alia M N WelshDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States.
Christopher J SchulzeRevolution Medicines, Inc., Redwood City, CA, United States.
Tiffany J ChoyRevolution Medicines, Inc., Redwood City, CA, United States.
Tram NguyenRevolution Medicines, Inc., Redwood City, CA, United States.
Neil OmaqueRevolution Medicines, Inc., Redwood City, CA, United States.
Yongmei HuDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States.
Mallika SinghRevolution Medicines, Inc., Redwood City, CA, United States.
Rich HansenRevolution Medicines, Inc., Redwood City, CA, United States.
Mark A GoldsmithRevolution Medicines, Inc., Redwood City, CA, United States.
Elsa QuintanaRevolution Medicines, Inc., Redwood City, CA, United States.
Jacqueline A M SmithRevolution Medicines, Inc., Redwood City, CA, United States.
Clifford A LowellDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States.
Revolution Medicines (United States) · USUniversity of California, San Francisco · US

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2003 to 2019
$21.8M
NIDDK NIH HHS P30 DK063720
6 · The paper itself

Abstract

Shp1, encoded by the gene

Indexed as

Adaptive ImmunityAdenocarcinomaAnimalsAntigens, DifferentiationColonic NeoplasmsFemaleHumansImmunity, InnateLymphocytes, Tumor-InfiltratingMelanoma, ExperimentalMice, Inbred C57BLMice, KnockoutPhagocytosisProtein Tyrosine Phosphatase, Non-Receptor Type 6Receptors, ImmunologicSignal TransductionAntigens, DifferentiationProtein Tyrosine Phosphatase, Non-Receptor Type 6PTPN6 protein, humanPtpn6 protein, mouseReceptors, ImmunologicSIRPA protein, humanSirpa protein, mouseimmuno-oncologyinflammationphagocytosisPTPN6SIRPαtyrosine phosphatase

Identifiers

PMID33133093
PMCPMC7550718
OpenAlexW3089940214

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.